|Videos|December 22, 2022

Stages and Progression of T1D

Author(s)Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, Kimberly Simmons, MD

Kimberly Simmons, MD, reviews stages 1, 2, and 3 of pediatric T1D progression.

Episodes in this series

EP. 1 Prevalence and Risk Factors of Pediatric Type 1 Diabetes (T1D)

EP. 1 Prevalence and Risk Factors of Pediatric Type 1 Diabetes (T1D)

EP. 2 Stages and Progression of T1D

EP. 2 Stages and Progression of T1D

EP. 3 Importance of Screening for T1D

EP. 3 Importance of Screening for T1D

EP. 4 Lifestyle Management in T1D

EP. 4 Lifestyle Management in T1D

EP. 5 Approaching T1D Screening Retesting

EP. 5 Approaching T1D Screening Retesting

EP. 6 Emerging Treatments in T1D

EP. 6 Emerging Treatments in T1D

EP. 7 Blood Glucose Monitoring in T1D

EP. 7 Blood Glucose Monitoring in T1D

EP. 8 Key Takeaways for Screening and Diagnosis of T1D

EP. 8 Key Takeaways for Screening and Diagnosis of T1D

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Family history alone may not prompt type 1 diabetes screening, survey finds | Image Credit: © Africa Studio - stock.adobe.com

Family history alone may not prompt type 1 diabetes screening, survey finds

ByMorgan Ebert, Executive Editor

July 30th 2026

Tzield approved to preserve insulin production in children with newly diagnosed type 1 diabetes

Tzield approved to preserve insulin production in children with newly diagnosed type 1 diabetes

ByMorgan Ebert, Executive Editor

June 15th 2026

ADA 2026 data highlight pediatric outcomes and treatment satisfaction with Afrezza

ADA 2026 data highlight pediatric outcomes and treatment satisfaction with Afrezza

ByMorgan Ebert, Executive Editor,Kevin Kaiserman, MD

June 11th 2026

Jamie Wood, MD, on the significance of the Afrezza approval for pediatric diabetes

Jamie Wood, MD, on the significance of the Afrezza approval for pediatric diabetes

ByJamie Wood, MD

June 4th 2026

Kevin Kaiserman, MD, discusses the impact of the first inhaled insulin approval for pediatrics

Kevin Kaiserman, MD, discusses the impact of the first inhaled insulin approval for pediatrics

ByKevin Kaiserman, MD

May 29th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Trending on Contemporary Pediatrics

Nonsteroidal topical therapies expand treatment options for pediatric skin conditions

Eczema, delayed allergen introduction, and early antibiotics top list of childhood food allergy risk factors

Trump signs executive order overhauling childhood vaccine recommendations

What Pediatricians Should Know About JAK Inhibitors Before Referral

Study: Breast milk and infant gut microbiota shift over first 8 postpartum weeks